Acute intermittent porphyria (AIP) is an inherited metabolic disorder that is characterized by abnormalities in the production of heme, a component of hemoglobin. Symptoms of AIP include severe abdominal pain, nausea, vomiting, constipation, and neurological problems. The increasing prevalence of AIP globally is driving the need for effective diagnostic tools and treatment options.
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Key Takeaways
Key players operating in the acute intermittent porphyria market are Alnylam Pharmaceuticals, Inc., MetroRx and Siemens Healthineers AG, among others.
Key opportunities in the Acute Intermittent Porphyria Market include development of new treatment options and expansion in emerging markets. The major players are focusing on expansion in countries with high disease prevalence such as Europe and the United States.
Market Drivers
Rising disease prevalence: The increasing incidence of AIP globally is a major factor augmenting the demand for diagnostic tools and therapeutics. According to estimates, 1 in 10,000 individuals suffer from AIP worldwide.
Availability of effective treatment options: Introduction of novel drugs such as Alnylam's Oxlumo, which received FDA approval in 2019, has significantly improved disease management and increased treatment rates.
Market Restraints
Lack of awareness: AIP is often misdiagnosed as other conditions due to low awareness among healthcare professionals and patients about its symptoms and diagnostic process. This poses a major challenge to market growth.
High cost of treatment: Treatment of an acute attack involves hospitalization, monitoring and use of expensive medications which increases the overall cost burden. This decreases treatment affordability in developing countries.
Segment Analysis
This market can be segmented based on drug types, such as dihydropteroate synthase inhibitors, hemin, and supportive care. Among them, the hemin segment dominated the market in 2020 as it is the only approved drug for the treatment of acute attacks of AIP. Hemin inhibits the accumulation of aminolevulinic acid and porphobilinogen in patients with AIP. The supportive care segment is also growing owing to rising adoption of pain medication, glucose supplementation, and intravenous fluid administration to manage pain and other symptoms associated with acute attacks.
Global Analysis
Regionally, North America holds the largest share in the acute intermittent porphyria market and is expected to continue its dominance during the forecast period. Factors such as the increasing prevalence of AIP, rising awareness about the disease, strong reimbursement policies, and availability of advanced healthcare facilities drive the growth of this regional market. Europe is the second-largest regional market due to the rising government support for improving healthcare infrastructure. Meanwhile, the Asia Pacific region is expected to show the highest growth over the forecast period owing to improving access to diagnosis and treatment, rising healthcare expenditure, and increasing focus of market players on expanding their presence in emerging Asian countries.
Get This Report in Japanese Language: 急性間欠性ポルフィリン症市場
Get This Report in Korean Language: 급성 간헐성 포르피린증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
Acute Intermittent Porphyria Market HighlightsAlthough the prevalence of this disease is considered rare.
It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin.
Children have a 50% chance of inheriting any of the 8 different types of porphyria if their parents have the disorder.Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R, and availability of funds drive the growth of Acute Intermittent Porphyria Market.
Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period.
However, high cost of the treatment may slow the Acute Intermittent Porphyria Market growth during the period 2017-2023.The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023.Acute Intermittent Porphyria Market Regional AnalysisThe Americas dominate the global acute intermittent porphyria market owing to the presence of huge patient population with gastrointestinal problems, neurological issues, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global acute intermittent porphyria market as result of increasing focus of various government agencies on the treatment of rare diseases such as acquired aplastic anemia.
